- Home
- ACRS vs TSI Comparison
ACRS vs TSI Comparison
Compare ACRS & TSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- TSI
- Stock Information
- Founded
- ACRS 2012
- TSI 1987
- Country
- ACRS United States
- TSI United States
- Employees
- ACRS N/A
- TSI N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- TSI Investment Managers
- Sector
- ACRS Health Care
- TSI Finance
- Exchange
- ACRS Nasdaq
- TSI Nasdaq
- Market Cap
- ACRS 198.2M
- TSI 235.1M
- IPO Year
- ACRS 2015
- TSI N/A
- Fundamental
- Price
- ACRS $2.26
- TSI $4.93
- Analyst Decision
- ACRS Strong Buy
- TSI
- Analyst Count
- ACRS 9
- TSI 0
- Target Price
- ACRS $9.25
- TSI N/A
- AVG Volume (30 Days)
- ACRS 1.5M
- TSI 106.8K
- Earning Date
- ACRS 11-06-2025
- TSI 01-01-0001
- Dividend Yield
- ACRS N/A
- TSI 7.46%
- EPS Growth
- ACRS N/A
- TSI N/A
- EPS
- ACRS N/A
- TSI N/A
- Revenue
- ACRS $16,789,000.00
- TSI N/A
- Revenue This Year
- ACRS N/A
- TSI N/A
- Revenue Next Year
- ACRS N/A
- TSI N/A
- P/E Ratio
- ACRS N/A
- TSI N/A
- Revenue Growth
- ACRS N/A
- TSI N/A
- 52 Week Low
- ACRS $1.05
- TSI $4.48
- 52 Week High
- ACRS $5.17
- TSI $4.87
- Technical
- Relative Strength Index (RSI)
- ACRS 53.36
- TSI 48.61
- Support Level
- ACRS $2.24
- TSI $4.88
- Resistance Level
- ACRS $2.70
- TSI $4.96
- Average True Range (ATR)
- ACRS 0.23
- TSI 0.04
- MACD
- ACRS 0.01
- TSI 0.00
- Stochastic Oscillator
- ACRS 46.34
- TSI 73.08
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.